 |
市场调查报告书
商品编码
1469300
PLK 标靶治疗的全球市场：市场机会、临床试验趋势（2024 年）Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 |
||||||
PLK 控制细胞週期的几个步骤，包括有丝分裂、中心体成熟、纺锤体形成、染色体分离和胞质分裂。 它还涉及 DNA 损伤反应和检查点控制系统。 在各种癌症类型中都观察到 PLK 的过度表现和失调，导致细胞增殖失控、基因组不稳定以及对化疗和放疗的抗药性。 抑制 PLK 会诱导有丝分裂灾难，导致癌细胞週期停滞和细胞凋亡。
还有新的证据表明，PLK可能参与免疫细胞功能和发炎的调节，并有可能在狼疮、类风湿性关节炎和多发性硬化症等自体免疫疾病中发挥作用，已成为治疗靶点。 此外，一些病毒，如人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV），会劫持宿主的PLK 进行复製并引起疾病，而针对PLK 的治疗可以破坏这些过程，有人认为抑制病毒可能会发挥作用。
PLK标靶治疗在製药业的前景看好。 持续的研究和开发、新药发现技术和临床进展预计将推动下一代 PLK 标靶治疗的开发，提高疗效和安全性。 PLK抑制剂可与其他抗癌药物合併使用，以提高治疗效果并克服抗药性机制。 此外，随着我们对各种癌症和疾病的遗传和分子谱的了解不断加深，PLK 标靶疗法可能会使用生物标记和遗传指纹来针对特定患者群体进行客製化。
本报告检视了全球 PLK 标靶治疗市场，并提供了市场概况，包括药物趋势、临床试验趋势、区域趋势以及进入市场的公司的竞争格局。
目录
第1章研究方法
第2章 PLK 标靶治疗简介
第3章 PLK 标靶治疗的临床方法
- 小分子抑制剂
- RNA干扰
- 反义寡核甘酸
- PROTAC分解器
第4章PLK标靶治疗的临床应用（按适应症）
- 癌症
- 微生物感染
- 自体免疫疾病
第5章 PLK标靶治疗的合併策略
- 与化疗合併使用
- 与免疫疗法结合
- 与标靶治疗结合
第6章 PLK 标靶治疗市场概述
- 当前市场趋势
- 未来商业化的前景
第7章 PLK 标靶治疗市场动态
- 市场驱动因素与机遇
- 市场挑战与限制因素
第8章全球PLK标靶治疗临床试验概述
- 爱别
- 依国家/地区
- 按公司
- 依指示
- 依优先权
- 患者部分
第 9 章依公司、国家和适应症对 PLK 标靶治疗临床试验的考量
- 研究
- 临床前
- 第一阶段
- 第一/二期
- 第二阶段
- 第三阶段
第10章竞争态势
- Biogenera
- Boehringer Ingelheim
- Cardiff Oncology
- Cyclacel Pharmaceutical
- Korea United Pharm
- ORIC Pharmaceuticals
- Pdx Pharmaceuticals
- Repare Therapeutics
- SillaJen Biotherapeutics
- Treadwell Therapeutics
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:
- PLK Targeted Therapies In Clinical Trials: > 10 Therapies
- USA Domination PLK Therapies Clinical Development Landscape: > 5 Therapies
- Breast Cancer Targeted Therapies In Clinical Trials: > 5 Therapies
- PLK Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
- Insight On Key Companies Involved In Development Of PLK Therapies
- PLK Targeted Therapy Combination Strategies With Chemotherapies, Immunotherapies & Targeted Therapies
Polo-like kinases (PLKs) are a group of serine/threonine kinases that play important roles in a variety of cellular processes, including cell cycle regulation, mitosis, DA damage response, and cytokinesis. Because of their role in these crucial processes, PLKs have emerged as promising therapeutic targets in cancer and other diseases. Though the market for PLK targeted therapies is still in its early stages, several pharmaceutical companies are investing in their research with the objective of improving the treatment of a variety of common ailments.
PLKs regulate several stages of the cell cycle, including mitosis, centrosome maturation, spindle assembly, chromosomal segregation, and cytokinesis. They also take part in DNA damage response and checkpoint control systems. Overexpression and dysregulation of PLKs have been observed in various types of cancer, contributing to uncontrolled cell proliferation, genomic instability, and resistance to chemotherapy and radiation therapy. Inhibition of PLKs can induce mitotic catastrophe, leading to cell cycle arrest and apoptosis in cancer cells.
Emerging evidence also suggests that PLKs may be involved in the regulating of immune cell function and inflammation, making them potential targets for autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis. Further, some viruses, like human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hijack host PLKs for their replication and pathogenesis, suggesting that PLK targeted therapies may have antiviral effects by dampening these processes.
As a result of these growing investigations, various small molecule inhibitors of PLKs have been found and are being developed, with some currently in clinical trials. Onvansertib, a PLK1 inhibitor developed by Cardiff Oncology, is currently the most advanced candidate in clinical trials. Onvansertib is being studied in a phase 2 trial to determine its safety and efficacy in patients with small cell lung cancer (SCLC) who have not responded to or are unable to tolerate chemotherapy. Aside from being researched in several solid malignancies, Onvansertib is currently undergoing a phase 1 trial to determine its efficacy and safety in the treatment of patients with recurrent or refractory chronic myelomonocytic leukemia.
Other candidates in the pipeline include RP-1664 and BAL0891, which are being assessed in solid cancers and CFI-400945, being studied for various hematological cancers. The progression of these candidates through the pipeline reflects the growing interest and confidence in PLK targeted therapies.
In addition to small molecule inhibitors, antisense oligonucleotides and PROTACs (proteolysis-targeting chimeras) are being investigated as potential PLK targets. Antisense oligonucleotides can selectively reduce PLK mRNA expression, whereas PROTACs cause proteasomal breakdown of PLK proteins, providing alternative methods to conventional kinase inhibitors. While these methods have shown promise in research and preclinical trials, their clinical implementation has proven difficult for a variety of reasons. However, ongoing research seeks to create more selective and powerful alternatives with better safety profiles.
As interest in PLK targeted therapies grows, pharmaceutical companies will have an opportunity to create and commercialize innovative PLK inhibitors or other PLK-targeting modalities. PLK inhibitors, degraders, and silencers have the potential to meet unmet medical needs in cancer, autoimmune disorders, and viral diseases, making them a valuable market opportunity. Established pharmaceutical corporations may seek alliances and partnerships with academic institutions or biotech companies to work on PLK targeted therapies, leveraging their experience and accelerating the development of novel treatments.
Looking ahead, the future of PLK targeted therapies in the pharmaceutical sector is promising. Continued research efforts, novel drug discovery techniques, and clinical advances will propel the development of next-generation PLK targeted therapies with enhanced efficacy and safety profiles. PLK inhibitors may be used in combination with other anticancer treatments to improve therapeutic efficacy and overcome resistance mechanisms. Furthermore, as our understanding of the genetic and molecular profiles of various cancers and disorders grows, PLK-targeted therapies may be customized to specific patient populations using biomarkers or genetic fingerprints.
In conclusion, PLK targeted therapies are a rapidly developing field with revolutionary promise across a wide range of disease areas. While significant progress has been made in the development of small molecule inhibitors and alternative modalities targeting PLKs, ongoing research and clinical trials are required to address challenges and unlock the full potential of this promising therapeutic approach. As research progresses and clinical data accumulate, the pharmaceutical industry is poised to capitalize on the therapeutic promise of PLK inhibition, shaping the future landscape of precision medicine and patient care.
Table of Contents
1. Research Methodology
2. Introduction to PLK Targeted Therapy
- 2.1 Overview
- 2.2 Development & Evolution
3. PLK Targeted Therapy Clinical Approaches
- 3.1 Small Molecule Inhibitors
- 3.2 RNA Interference
- 3.3 Antisense Oligonucleotides
- 3.4 PROTAC Degraders
4. PLK Targeted Therapy Clinical Application by Indication
- 4.1 Cancer
- 4.1.1 Overview
- 4.1.2 Ongoing Research & Development
- 4.2 Microbial Infections
- 4.3 Autoimmune Diseases
5. PLK Targeted Therapy Combination Strategies
- 5.1 Combination with Chemotherapies
- 5.2 Combination with Immunotherapies
- 5.3 Combination with Targeted Therapies
6. PLK Targeted Therapies Market Overview
- 6.1 Current Market Trends
- 6.2 Future Commercialization Outlook
7. PLK Targeted Therapies Market Dynamics
- 7.1 Market Drivers & Opportunities
- 7.2 Market Challenges & Restraints
8. Global PLK Targeted Therapies Clinical Trials Overview
- 8.1 By Phase
- 8.2 By Country
- 8.3 By Company
- 8.4 By Indication
- 8.5 By Priority Status
- 8.6 Patient Segment
9. PLK Targeted Therapies Clinical Trials insight By Company, Country & Indication
- 9.1 Research
- 9.2 Preclinical
- 9.3 Phase I
- 9.4 Phase I/II
- 9.5 Phase II
- 9.6 Phase III
10. Competitive Landscape
- 10.1 Biogenera
- 10.2 Boehringer Ingelheim
- 10.3 Cardiff Oncology
- 10.4 Cyclacel Pharmaceutical
- 10.5 Korea United Pharm
- 10.6 ORIC Pharmaceuticals
- 10.7 Pdx Pharmaceuticals
- 10.8 Repare Therapeutics
- 10.9 SillaJen Biotherapeutics
- 10.10 Treadwell Therapeutics
List of Figures
- Figure 2-1: Some Biological Functions of PLKs
- Figure 2-2: PLK-Targeted Therapies - Chronology of Events
- Figure 4-1: Rigosertib Early Phase 1 (NCT04177498) Study - Initiation & Completion Year
- Figure 4-2: Rigosertib Phase 1/2a (NCT04263090) Study - Initiation & Completion Year
- Figure 4-3: Rigosertib Phase 2 (NCT05764395) Study - Initiation & Completion Year
- Figure 4-4: Onvansertib Phase 2 (NCT06106308) Study - Initiation & Completion Year
- Figure 4-5: Onvansertib Phase 2 (NCT05450965) Study - Initiation & Completion Year
- Figure 4-6: Onvansertib Phase 1 (NCT05549661) Study - Initiation & Completion Year
- Figure 4-7: Ocifisertib Phase 1/2 (NCT04730258) Study - Initiation & Completion Year
- Figure 4-8: Ocifisertib Phase 2 (NCT03624543) Study - Initiation & Completion Year
- Figure 4-9: Ocifisertib Phase 1 (NCT03187288) Study - Initiation & Completion Year
- Figure 4-10: RP-1664 Phase 1 (NCT06232408) Study - Initiation & Completion Year
- Figure 4-11: Plogosertib Phase 1 (NCT05358379) Study - Initiation & Completion Year
- Figure 4-12: BAL0891 Phase 1 (NCT05768932) Study - Initiation & Completion Year
- Figure 6-1: PLK Targeted Therapies - Future Opportunities
- Figure 7-1: PLK Targeted Therapies Market - Drivers & Opportunities
- Figure 7-2: PLK Targeted Therapies Market - Challenges & Restraints
- Figure 8-1: Global - PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
- Figure 8-2: Global - PLK Targeted Therapies Clinical Pipeline by Country (Numbers), 2024
- Figure 8-3: PLK Targeted Therapies Clinical Pipeline by Company (Numbers), 2024
- Figure 8-4: Global - PLK Targeted Therapies Clinical Pipeline by Indication (Numbers), 2024
- Figure 8-5: Global - PLK Targeted Therapies Clinical Pipeline by Fast Track Designation (Numbers), 2024
- Figure 8-6: Global - PLK Targeted Therapies Clinical Pipeline by Patient Segment (Numbers), 2024
List of Tables
- Table 5-1: PLK Inhibitor & Chemotherapy Combinations in Clinical Trials, April'2024
